Salarius Pharmaceuticals (NASDAQ:SLRX) Stock Price Down 2.6% – Should You Sell?

Shares of Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) were down 2.6% on Monday . The company traded as low as $0.62 and last traded at $0.64. Approximately 196,853 shares changed hands during trading, a decline of 35% from the average daily volume of 304,344 shares. The stock had previously closed at $0.6573.

Analyst Upgrades and Downgrades

SLRX has been the topic of several research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Salarius Pharmaceuticals in a research report on Monday, December 22nd. Wall Street Zen raised Salarius Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Salarius Pharmaceuticals Stock Performance

The firm has a market capitalization of $3.75 million, a PE ratio of -0.02 and a beta of 0.40. The firm’s 50 day moving average price is $1.61 and its 200-day moving average price is $5.89.

Salarius Pharmaceuticals (NASDAQ:SLRX) last issued its quarterly earnings results on Friday, November 14th. The company reported ($1.81) EPS for the quarter, topping the consensus estimate of ($33.60) by $31.79.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that target epigenetic and post‐translational modification pathways in cancer. The company’s lead candidate, seclidemstat (SP‐2577), is designed to inhibit lysine‐specific demethylase 1 (LSD1) and modulate the tumor microenvironment, with a primary focus on treating Ewing sarcoma, a rare and aggressive bone and soft tissue cancer affecting children and young adults.